Physician Photo

Lawrence R. Zukerberg, MD

Associate Pathologist, Massachusetts General Hospital

Associate Professor of Pathology, Harvard Medical School

Dr. Zukerberg has expertise in gastrointestinal, hematological, and frozen section pathology.

Department of Pathology


  • Cancer Center
  • Multiple Myeloma
  • Lymphoma
  • Thymoma
  • Pancreatic Cancer
  • Liver Cancer
  • Hematology
  • Gastrointestinal Cancers
  • Leukemia
  • Hodgkin Lymphoma
Clinical Interests
Gastrointestinal cancer
Liver cancer
Pancreatic cancer
Boston: Massachusetts General Hospital
Medical Education
MD, UMDNJ Rutgers Medical School
Residency, Massachusetts General Hospital
Fellowship, Massachusetts General Hospital
Fellowship, University of Michigan Hospitals
Board Certifications
Anatomic Pathology & Clinical Pathology, American Board of Pathology
Patient Age Group
Accepting New Patients
Accepting New Patients


Dr. Zukerberg has expertise in gastrointestinal, hematological, and frozen section pathology. He is the  Principal Investigator with a research program focused on studying the biology and biochemistry of a novel gene, Cables that interacts with cell cycle control proteins including, CDK2, p53, beta-catenin, mTOR and is a novel cell cycle regulator and tumor suppressor gene.  Cables expression is lost in many primary human cancer and it loss can prolong the life of stem cells in some mouse organs.  Some of the research projects of Dr. Zukerberg include studying the relationship of Cables to cell cycle control proteins, generating and studying Cables mutant mice, and determining the pathways involved in Cables cell growth regulation. Other recent projects have included identification of cyclin D1 as a marker of mantle cell lymphoma and understanding specific reactive conditions that mimic lymphoma.


We have recently cloned a novel protein, Cables, which maps to human chromosome 18q and inhibits growth of cells in culture and tumor formation in animal models. Our studies will define a novel target for the deletions commonly seen on chromosome 18q. Ultimately, these studies will lay the foundation for new therapeutic approaches.  See details at the Zukerberg Lab. For more information about research concepts, co-authors, and to see a timeline, visit Dr. Zukerberg's profile at the Harvard Clinical and Translational Science Center.


View my most recent publications at PubMed

  1. Age and Obesity Promote Methylation and Suppression of 5-Alpha Reductase 2- Implications for Personalized Therapy in Benign Prostatic Hyperplasia. Bechis SK, Otsetov AG, Ge R, Wang Z, Vangel MG, Wu CL, Tabatabaei S, Olumi AF. J Urol. 2015 Apr 24. pii: S0022-5347(15)03861-6. doi: 10.1016/j.juro.2015.04.079. [Epub ahead of print]
  2. Succinate dehydrogenase B: a new prognostic biomarker in clear cell renal cell carcinoma. Cornejo KM, Lu M, Yang P, Wu S, Cai C, Zhong W, Olumi A, Young RH, Wu CL.Hum Pathol. 2015 Mar 11. pii: S0046-8177(15)00079-9. doi: 10.1016/j.humpath.2015.02.013. [Epub ahead of print]
  3. Aberrant hypomethylation-mediated CD147 overexpression promotes aggressive tumor progression in human prostate cancer.Liang YX, Mo RJ, He HC, Chen JH, Zou J, Han ZD, Lu JM, Cai C, Zeng YR, Zhong WD, Wu CL. Oncol Rep. 2015 May;33(5):2648-54. doi: 10.3892/or.2015.3870. Epub 2015 Mar 20.

Pathology Associates
55 Fruit Street
Boston, MA 02114-2696

Phone: 617-726-2967
Fax: 617-724-7803